BCL-6 gene alterations have been observed in 27 ± 45% of diuse large B-cell lymphomas (DLBs) with chromosomal translocations at 3q27. The deregulated expression of normal BCL-6 protein caused by this chromosomal translocation is believed to be responsible for lymphomagenesis. Recently, we demonstrated that BCL-6 is expressed at high levels in germinal center B-cells as a 92-98 kDa nuclear protein in a constitutively phosphorylated form. In this study, we show that BCL-6 is phosphorylated by mitogen-activated protein kinase (MAPK) in vitro at the sites phosphorylated in vivo. These numerous phosphorylation sites were found to be located in its serine-and proline-clustered (SPC) region (amino acids-250-483). BCL-6 phosphorylation signi®-cantly increased in Ramos cells following stimulation with 12-o-tetradecanoylphorbol-13-acetate (TPA) or BCL-6-and erk1-transfected COS-7 cells stimulated with epidermal growth factor (EGF), and the increase of phosphorylation was inhibited by MEK1 inhibitor, PD98059. Furthermore, we observed that BCL-6 was associated with MAPK in vivo and its SPC region was important for this association. These results suggest that the functions of BCL-6 are regulated by phosphorylation mediated by the MAPK signaling pathway.
Introduction
Recently, the BCL-6 gene was identi®ed on human chromosome 3q27, adjacent to the break-points of a chromosomal translocation which is observed frequently in diuse large-B-cell lymphomas (DLBs) (Kerckaert et al., 1993; Ye et al., 1993; Miki et al., 1994) . Rearrangement of the BCL-6 gene has been found in 27 ± 45% of DLBs and 5 ± 14% of follicular lymphomas (Bastard et al., 1994; Lo Coco et al., 1994) . Furthermore, one recent clinicopathological study demonstrated that BCL-6 gene rearrangement is correlated with patient outcomes , although another group failed to detect such a statistical association (Bastard et al., 1994) . Therefore, BCL-6 gene alterations are probably associated with the pathogenesis of some subtypes of nonHodgkin's lymphoma (NHL) and possibly with the clinical disease status.
The BCL-6 gene encodes a protein containing a DNA binding domain consisting of six C-terminal zinc®nger motifs Baron et al., 1995) , and an N-terminal BTB/POZ domain, which was found to act as a protein-protein interaction domain (Bardwell and Treisman, 1994; Zollman et al., 1994) . Conserved N-terminal BTB/POZ and Cterminal zinc-®nger domains have also been identi®ed in some transcription factors, such as the Drosphila tramtrack (ttk) protein (Harrison and Travers, 1990) , Broad-complex (Br-c) protein (DiBello et al., 1991) , human KUP protein (Chardin et al., 1991) and ZID protein (Bardwell et al., 1994) , suggesting that BCL-6 acts as a transcription factor.
We and another group reported recently that BCL-6 is a 92 ± 98 kDa nuclear phosphoprotein and is expressed at high levels in germinal center B-cells (Onizuka et al., 1995; Cattoretti et al., 1995) . Furthermore, we found recently that not only B-and T-lymphocytes, but also granulocytes and monocytes expressed high levels of BCL-6 transcripts, and that their expression levels increased concomitant with myelo/monocytic lineage dierentiation (Yamochi et al., in press ). These results led us to speculate that BCL-6 plays a role in the regulation of dierentiation at a speci®c maturation stage of various hematopoietic lineages.
In a previous study, we found that BCL-6 was expressed in a constitutively phosphorylated form (Onizuka, et al., 1995) . As phosphorylation of transcription factors is thought to be important for their functional regulation, including the regulation of nuclear translocation. DNA binding and transcriptional activity (Hunter and Karin, 1992) , we imagined that the function of BCL-6 may be regulated by phosphorylation. Thus, we set out to elucidate the mechanisms involved in BCL-6 phosphorylation in order to understand its possible function.
In this study, we demonstrated that BCL-6 is phosphorylated at its serine-and proline-clustered (SPC) region by mitogen-activated protein kinase (MAPK) in vitro and in vivo. Furthermore, we showed that the SPC region of BCL-6 is involved in the association of this protein with MAPK in vivo. Sanghera et al., 1992a) , and ®rst tested whether MAPK and Jun N-terminal kinase (JNK) are able to phosphorylate BCL-6 in vitro. Full-length BCL-6 fused to glutathione S-transferase [GST-BCL-6 (1-706)] bound to glutathione-Sepharose beads was incubated with [g-32 P]ATP and puri®ed MAPK or JNK. As shown in Figure 1a , MAPK phosphorylated GST-BCL-6 (1-706), but not GST alone. By contrast, JNK could not phosphorylate GST-BCL-6 (1-706), although it eciently phosphorylated GST-c-Jun (1-169). Next, deletion mutants of GST-BCL-6 were generated ( Figure 1b ) and subjected to this in vitro phosphorylation reaction. As shown in Figure 1a , one fragment containing a serine-and proline-clustered region (SPC region, amino acids 250-483) was phosphorylated eciently by MAPK, but the other fragments containing amino acids 1-181 [GST- (1-181)] and 511-706 [GST-BCL-6 (511-706)] were not phosphorylated. These results suggest that the SPC region contains sites for phosphorylation by MAPK.
BCL-6 is phosphorylated at multiple sites in its SPC region by MAPK in vitro As described previously (Onizuka et al., 1995) , the two anti-BCL-6 polyclonal antibodies (a-2FR and a-3FR) immunoprecipitated a 92-98 kDa BCL-6 from [ 32 P]-orthophosphate-labeled Ramos cells (Figure 2a ). Phosphopeptide mapping of this immunoprecipitated protein yielded 22 to 24 spots (Figure 2b , panel A), whereas phosphopeptide mapping of GST-BCL-6 (1-706) phosphorylated by MAPK in vitro yielded 17 spots (Figure 2b, panel B) . The mapping patterns of BCL-6 phosphorylated in vitro and in vivo were very similar. A mixing experiment con®rmed that all the 17 spots generated in vitro from the phosphorylated protein comigrated with spots generated from BCL-6 labeled in vivo ( Figure 2b , panel C), although six spots (4, 10, 11, 12, 16 and 20) were very weak on maps generated from BCL-6 phosphorylated in vitro by MAPK (Figure 2b , panel B). Phosphoamino acid analysis revealed that BCL-6 was phosphorylated primarily at serine residue ( Figure 3 ). These results suggest that the SPC region is phosphorylated by MAPK in vivo.
Activation of MAPK enhances BCL-6 phosphorylation
Next, we tried to determine whether BCL-6 phosphorylation increased in parallel with MAPK activation. We transfected the BCL-6-and/or erk-1 gene(s) into COS-7 cells. The cells were then cultured in serum-reduced medium (0.1% vol/vol FCS) for 3 h prior to harvesting. For the ®nal 2.5 h of culture, the cells were labeled metabolically with [ 35 S]-methionine or [ 32 P]-orthophosphate. After exposure to EGF plus serum (10% vol/vol FCS) for 5 min, the cells were harvested and immunoprecipitated with a-2FR. As shown in Figure 4a , the level of phosphorylation of BCL-6 in COS-7 cells transfected with BCL-6 and erk-1 was higher than that in cells transfected with BCL-6 alone. Meanwhile, BCL-6 phosphorylation in COS-7 cells transfected with BCL-6 alone was enhanced by treating the cells with EGF, but was not detected in untransfected COS-7 cells. Moreover, when the cells transfected with both BCL-6 and erk-1 were treated with EGF, BCL-6 phosphorylation was further signi®cantly increased (lanes 6, 12). The relatively slight enhancement of phosphorylation by EGF observed in COS-7 cells transfected with BCL-6, but not with erk-1, may have been due to the activation of endogenous MAPK. Phosphopeptide mapping analysis showed that the patterns generated from cotransfected cells stimulated with EGF and control cells were very similar (Figure 4b ).
To further analyse the BCL-6 phosphorylation by MAPK in B-cells, Ramos cells expressing both BCL-6 and MAPK endogenously were stimulated with TPA by which MAPK signaling cascade was activated. The BCL-6 phosphorylation by TPA-stimulation was enhanced slightly as was shown by the slower migration of the band in SDS-gel (Figure 4c became signi®cantly phosphorylated (Figure 5a ), suggesting that a protein kinase(s) co-immunoprecipitated with and phosphorylated BCL-6. Very similar results were obtained with two dierent antibodies (a-2FR and a-3FR), which recognize distinct domains of this protein (Onizuka et al., 1995) (Figure 5a ). When the immunoprecipitates were denatured by exposure to 1% wt/vol SDS, boiled for 2 min, diluted to produce The samples were applied to the sites indicated by arrowheads on thinlayer cellulose plates and fractionated in the ®rst dimension by electrophoresis (cathode to the right) and in the second dimension by ascending chromatography with phosphochromatography buer
Phosphorylation of BCL-6 by MAPK in vivo M Moriyama et al 0.1% wt/vol SDS and then reimmunoprecipitated with a-3FR, this kinase activity was not detected ( Figure  5a ). Tryptic phosphopeptide mapping of BCL-6 phosphorylated by the co-immunoprecipitated kinase generated 7 spots, all of which were found to comigrate with spots yielded by BCL-6 labeled in vivo (Figure 5b ), although the spots 7 and 21 ( Figure 5b , panel B) were stronger than those generated from BCL-6 labeled in vivo. These results suggest that BCL-6 is associated with a protein kinase(s) in vivo.
Association of BCL-6 with MAPK in vivo Next, we analysed whether BCL-6 is associated with MAPK in vivo. First, Ramos and Molt 4 cells were solubilized, and the lysates were immunoprecipitated with a rabbit anti-MAP Kinase R2 (erk1-CT) polyclonal antibody (a-MAPK-CT). The precipitates were then subjected to immunoblotting with a-3FR. As shown in Figure 6a , a 92-98 kDa band corresponding to BCL-6 was detected in the precipitates from Ramos cells, but not in those from Molt 4 cells. This 92-98 kDa band was not detected when a-MAPK-CT was pre-incubated with an excess amount of the immunizing peptides. Similarly, when Ramos cells were labeled metabolically with [ A mixing experiment revealed that almost all the a-MAPK-CT-immunoprecipitated spots co-migrated with the a-3FR-immunoprecipitated spots (Figure 6c ). These results suggest that the 92-98 kDa protein associated with MAPK is BCL-6. On the other hand, when anti-JNK1(C-17) polyclonal antibody, anti-JNK2(N-18) polyclonal antibody and anti-p38(C-20) polyclonal antibody were used for the co-immunoprecipitation study, we could not detect the 92-98 kDa band corresponding to BCL-6 (data not shown).
The SPC region of BCL-6 is important for its association with MAPK In order to identify the MAPK-binding site in BCL-6, we incubated cell lysates extracted from Ramos cells with full length BCL-6 and its deletion mutants bound to glutathione-Sepharose beads. As shown in Figure 7 , the 42 and 44 kDa bands corresponding to ERK1 and ERK2 were found to be associated with GST-BCL-6 (1-706) and GST-BCL-6 (230-517), but not with GST, GST-BCL-6 (1-181) and GST-BCL-6 (511-706) when immunoblotted with a-MAPK-CT. These results were further con®rmed by immunoblotting with the use of another monoclonal antibody recognizing speci®cally the 42 kDa MAPK (ERK2), suggesting that the SPC region of BCL-6 is important for its association with MAPK.
Discussion
In the present study, we demonstrated that the MAPK (ERK1; p44/ERK2; p42), or a related kinase(s) with similar speci®city, is involved in the phosphorylation of BCL-6 in vivo. This conclusion was reached based on the following ®ndings. First, puri®ed MAPK eciently phosphorylated GST-BCL-6 in vitro in the SPC region which possesses a number of consensus phosphorylation sites (-SP-, -PXSP-, -PXXSP-) for MAPK. Second, the phosphopeptide map of GST-BCL-6 phosphorylated by puri®ed MAPK in vitro was shown to be very similar to that of BCL-6 immunoprecipitated from Ramos cells labeled in vivo. Third, BCL-6 phosphorylation was enhanced by the stimulation of cells with EGF or TPA, both of which are known to activate MAPK. Fourth, the MEK1 inhibitor, PD98059, inhibited the enhancement of BCL-6 phosphorylation in Ramos cells treated with TPA. Fifth, BCL-6 was shown to be associated with MAPK in vivo and the SPC region was revealed to be important for its association. At the same time, the phosphopeptide mapping pattern of the co-immunoprecipitated kinase activity was simpler than that generated from BCL-6 phosphorylated both in vitro and in vivo by MAPK. One explanation for this dierence is that solubilization of the BCL-6/MAPK complex in solubilizing buer may have altered its structural conformation, thereby changing the resulting kinase activity. Another explanation may be that the co-precipitated kinase activity is due to a kinase other than MAPK. In the present study, however, we found that JNK, a family member of MAPK, does not phosphorylate BCL-6. Although we cannot exclude at this moment the possibility that other kinases are involved in the phosphorylation of BCL-6, our present data strongly suggest that the function of BCL-6 is regulated by the MAPK signaling pathway. Phosphorylation of transcription factors by kinases activated by extracellular signals is thought to be one of the main mechanisms by which they are regulated. It has been reported that nuclear translocation, DNA-binding and transcriptional activity of some transcription factors can be modulated by phosphorylation either positively or negatively (Hunter and Karin, 1992) . For example, phosphorylation of SW15 by Cdc28 inhibits nuclear import (Nasmyth et al., 1990) , phosphorylation of SRF by casein kinasell (CKII) just upstream of the DNAbinding domain stimulates its DNA binding activity (Rivera et al., 1993) , and phosphorylation of c-Myc at ]-methionine (lanes 7 ± 12) in medium containing 0.1% vol/vol FCS for 4 h, and treated either with EGF plus 10% vol/vol FCS (lanes 1, 2, 5, 6, 7, 8, 11, 12) for 5 min or left untreated (lanes 3, 4, 9, 10). Cells were lysed and subjected to immunoprecipitation with a-2FR and the immunoprecipitates were subjected to SDS ± PAGE followed by autoradiography. (b) BCL-6 immunoprecipitated from BCL-6 and erk1 co-transfected COS-7 cells stimulated with EGF or untreated was subjected to two-dimensional tryptic phosphopeptide mapping 1, 3) . Cells were lysed and subjected to immunoprecipitation with a-2FR and the immunoprecipitates were subjected to SDS ± PAGE followed by autoradiography. (d) Ramos cells were precultured in serumreduced (0.1% vol/vol FCS) medium for 4 h, treated with PD98059 at a ®nal concentration of 10 mM (lane 3), 50 mM (lane 4) or 100 mM (lane 5) for 1 h, respectively, and then treated either with TPA (10 ng/ml) plus 10% vol/vol FCS (lane 2 ± 5) for 5 min or left untreated (lane 1). Subsequently, cells were collected, lysed and subjected to immunoprecipitation and immunoblotting with a-2FR. Bands corresponding to the antibody used for immunoprecipitation are indicated by the asterisk
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Ser-62 activates its transcriptional function . Recently, it has been reported that BCL-6 can represss transcription when bound to speci®c BCL-6-binding sequences inserted upstream of the thymidine kinase promoter (Chang et al., 1996; Seyfert et al., 1996) . By further analysis using BCL-6-deletion mutants, it was shown that two noncontigiuous domains, corresponding to the BTB/ POZ domain and to amino acids 267-395, were both necessary for maximal transrepression by BCL-6 (Chang et al., 1996) . Because the second transrepression domain (amino acids-267-395) is completely contained within the SPC region (amino acids-250-483), phosphorylation of the SPC region may contribute to its transcriptional regulation. Thus, one interesting possibility is that the transcriptional repression activity of BCL-6 may be regulated by phosphorylation through the MAPK signaling pathway. (A) and (B) . The samples were applied to the sites indicated by arrowheads on thin-layer cellulose plates and fractionated in the ®rst dimension by eletrophoresis (cathode to the right) and in the second dimension by ascending chromatography with phosphochromatography buer
Phosphorylation of BCL-6 by MAPK in vivo M Moriyama et al Furthermore, it has been reported that DNAbinding proteins often bind to DNA as homo-or hetero-dimers, and their DNA-binding activities can be regulated by phosphorylation (Hunter and Karin, 1992; Hill and Treisman, 1995) . For example, phosphorylation of homodimerized Max by CKII inhibits its DNA binding activity, although the function of the Myc-Max heterodimer is unaected by phosphorylation (Berberich and Cole, 1992) . Recently, the BTB/POZ domain of BCL-6 has been suggested to mediate homodimerization or association with another protein (Dhordain et al., 1995) . Thus, it is possible that the DNA-binding function of BCL-6 may also be regulated by phosphorylation of BCL-6 either homodimerized or in a heterocomplex with another protein.
Several transcription factors, such as Elk-1 (Gille et al., 1992; Marais et al., 1993) , c-Myc , c-Jun Pulverer et al., 1991) , c-Fos (O®r et al., 1990) , NF-IL-6 (Nakajima et al., 1993) , TAL-1 (Cheng et al., 1993) and AML-1 (Tanaka et al., 1996) have been proposed to be substrates for MAPK in vitro. Furthermore, it has been reported that Elk-1 (Rao and Reddy, 1994) , c-Myc (Gupta and Davis, 1994) and AML-1 (Tanaka et al., 1996) can associate with MAPK in vitro, whereas AP-1 can associate with MAPK in vivo (Bernstein et al., 1994) . Since many kinases have been shown to phosphorylate their candidate substrates only in vitro but not in vivo, the demonstration that a substrate can associate with the kinase in vivo is strong evidence that it is a speci®c substrate. In this context, it is highly probable that BCL-6 is a relevant substrate for MAPK.
On the other hand, binding between c-Jun and c-Jun amino-terminal kinases (JNKs), members of the MAPK family (Hibi et al., 1993; Derijard et al., 1994; Kallunki et al., 1994) have been reported. Very recently, Gupta et al. showed that both c-Jun and ATF-2 bind to and are phosphorylated by JNK, while JunB binds to but is not phosphorylated by JNK, and Elk-1 does not bind to but is phosphorylated by JNK, suggesting that the binding and phosphorylation may be distinct attributes of the interaction between JNKs and their target proteins (Gupta et al., 1996) . Thus, it can be speculated that the binding of BCL-6 with MAPK may also play multiple roles besides phosphorylation. If so, the transcriptional function of BCL-6 may be regulated directly by its binding to MAPK. Indeed, it has recently been reported that the aminoterminal BTB/POZ domain of BCL-6 mediates its homo-dimerization (Dhordain et al., 1995) and that the homodimerization on hetero-dimerization with another protein is important for its transcriptional repression (Seyfert et al., 1996) . Thus, it is possible that the function of BCL-6 may be regulated by protein-protein interaction.
MAPK has been shown to be involved in a broad spectrum of cellular events, including cell growth (Gotoh et al., 1991a, b; Pages et al., 1993; Mansour et al., 1994) , dierentiation and maturation (Kosako et al., 1994; Cowley et al., 1994; Kharbanda et al., 1994) . It was reported that MAPK is activated during TPAinduced monocytic lineage dierentiation in HL-60 cells (Kharbanda et al., 1994) . Meanwhile, we found recently that the expression of the BCL-6 gene is induced during monocytic lineage dierentiation in TPA-treated HL-60 and U-937 cells (Yamochi et al., in press ). Accordingly, the increased synthesis of BCL-6 after TPA-stimulation may be accompanied by a concomitant increase in phosphorylation, suggesting that the function of BCL-6 may possibly be regulated during monocytic dierentiation by phosphorylation dependent on the activation of MAPK.
Materials and methods

Antibodies
Two rabbit anti-BCL-6 polyclonal antibodies (a-2FR and a-3FR) were prepared as described previously (Onizuka et al., 1995) . A rabbit anti-MAP Kinase R2 (erk1-CT) polyclonal antibody (a-MAPK-CT) prepared by immunizing rabbits with synthetic peptides containing amino acids 333-367 of rat 43 kDa MAPK (Boulton et al., 1991) was purchased from Upstate Biotechnologies Inc. (UBI). This antibody is known to cross-react with human MAPKs (Sanghera et al., 1992a, b; Charest et al., 1993) . The peptides used for immunization [MAP Kinase R2 (erk1-CT) peptide; UBI] were also utilized for the absorption study. Another anti-MAP Kinase R2 (erk2) monoclonal antibody (a-MAPK-R2) recognizing speci®cally the 42 kDa MAPK (ERK2) was also purchased from UBI. Anti-JNK1(C-17) polyclonal antibody (Santa Cruz Biotech., Santa Cruz, CA), anti-JNK2(N-18) polyclonal antibody (Santa Cruz) and anti-p38(C-20) polyclonal antibody (Santa Cruz) were used for the co-immunoprecipitation study to know whether BCL-6 is associated with JNKs or p38 in vivo. Association of BCL-6 with MAPK in vitro. Ramos cells were lysed in 1% vol/vol NP40 solubilizing buer and were incubated for 30 min at 48C with full-length GST-BCL-6 bound to glutathione-Sepharose GST-BCL-6 (1-706) (lane 1, 7) and its deletion mutants (lane 2 ± 5, 8 ± 11). Then, the Sepharose beads were washed thoroughly and subjected to SDS ± PAGE and immunoblotting with a-MAPK-CT (lane 1 ± 6) or a-MAPK-R2 (lane 7 ± 12). As a positive control, 100 mg Ramos cell lysate was also subjected to Western blot analysis (lane 6, 12)
Synthesis of GST-BCL-6, GST-JNK
GST-BCL-6 (1-706) was constructed by inserting the BCL-6 cDNA sequence encoding amino acids 1-706 into the pGEX vector (Pharmacia). GST-BCL-6 (1-181), GST-BCL-6 (230-517) and GST-BCL-6 (511-706) were constructed as described previously (Onizuka et al., 1995) . These GST-BCL-6 proteins were synthesized in Escherichia Coli and puri®ed using glutathione-Sepharose (Pharmacia) as described previously (Onizuka et al., 1995) . To construct GST-JNK, the human jnk-2 cDNA was isolated by screening a cDNA library generated from Ramos cells, and the full length jnk-2 cDNA was inserted in-frame into the pGEX vector. GST-JNK was synthesized, puri®ed, eluted from the glutathione-Sepharose and then dialyzed against the kinase buer before subjecting to in vitro phosphorylation reaction. Agarose conjugated GST-cJun(1-169) (UBI) was used as the control substrate for JNK.
Cell culture and labeling
Ramos and Molt 4 cells were cultured in RPMI1640 (Gibco) containing 10% vol/vol fetal calf serum (FCS). For metabolic labeling with [ 32 P]-orthophosphate or [ 35 S]-methionine, the cells were washed twice with phosphate-or methionine-free RPMI1640 medium, respectively, and then incubated for 4 h at 378C with 0.5 mCi/ml [ 32 P]-orthophosphate (NEN) in phosphate-free medium or 100 mCi/ml [ 35 S]-methionine (Amersham) in methionine-free medium.
Transfection
Human erk1 cDNA was isolated from a cDNA library generated from the human B-cell line, Ramos, and cloned into the vector pCMV. Five 610 5 cells were transfected with 4 mg pMKIT-BCL-6 or the pMKIT vector together with 4 mg pCMV-erk1 or pCMV, respectively, using Lipofectin (Gibco-BRL). After incubation for 48 h, the cells were cultured in medium containing 0.1% vol/vol FCS for 3 h, and then treated with EGF plus 10% vol/vol FCS for 5 min. Subsequently, the cells were harvested and subjected to immunoprecipitation, followed by SDS ± PAGE and autoradiography.
Immunoprecipitation
Cells were collected by centrifugation, lysed on ice for 20 min in solubilizing buer [50 mM Tris-HCl pH 7.2, 1% vol/vol NP-40, 150 mM NaCl, 50 mM b-glycerophosphate, 5 mM dithiothreitol (DTT), 1 mM Na 3 VO 4 , 0.05 mM NaF, 0.1 mM (p-amidinophenyl)methanesulfonyl uoride and 5 mg/ml leupeptin], and centrifuged at 15 000 r.p.m. at 48C for 20 min, as described previously (Akiyama et al., 1992) . Lysates were incubated with the required antibodies for 1 h at 48C and the resulting immunocomplexes were adsorbed to protein G-Sepharose (Pharmacia), washed thoroughly with solubilizing buer and subjected to SDS ± PAGE.
In vitro phosphorylation reaction
In vitro phosphorylation experiments were performed using a MAP kinase assay kit (UBI). Puri®ed GST-BCL-6 protein (2 mg) adsorbed to glutathione sepharose beads or BCL-6 protein immunoprecipitated from Ramos cell lysates was incubated with puri®ed MAPK (50 ng) derived from sea star oocytes (MAP Kinase-mpk; UBI), assay buer and [g-32 P]ATP (10 mCi) at 308C for 30 min according to the manufacturer's instructions. Subsequently, the reaction products were subjected to SDS ± PAGE.
Two-dimensional tryptic phosphopeptide mapping and phosphoamino acid analysis of the phosphorylated BCL-6 Two-dimensional tryptic phosphopeptide mapping and phosphoamino acid analysis were performed according to the previously-described method (Boyle et al., 1991) .
